

Date

Award Committee
(NAME of the Program)

Re: Letter of Reference for nominating (NAME)

Dear Award Committee:
(Funding agency/Award program name)

I am writing to provide Yale Cancer Center (YCC)'s strongest support for Dr. (Name)'s application to (Funding agency's/Award program name) on (Name of the research area). (Description about the Cancer, epidemiology and related current data)

Please give a **short** description of your proposed research idea that includes:

1. Research Objective statement
2. Impact the specific research results will have for advancing cancer research or treatment, etc.
3. Innovation of the proposed idea
 - a. Novel technologies (or old technologies used in novel ways)
 - b. Optimal resources/Environment at YCC including peers and future collaborators that may contribute to the success of the project.
 - c. Improvement in personal clinical research goals and their positive impact on health care implementations.
4. If the RFA has a specific focus, a statement as to how the proposal addresses the foundation's research.

Yale School of Medicine created history in cancer chemotherapy by discovering the very first cancer drug and that was administered in 1942, thus opening the arena for entire field of cancer drug development. The legacy continues to provide timeless pieces that lives through collaboration of Yale Caner Center, Smilow Cancer Hospital, Yale University and Yale Medicine.

YCC is the sole representative of a comprehensive cancer center in Connecticut, designated by NIH since 1974 and the largest provider of cancer care treating 48% of the total cancer patients (20,000) diagnosed annually in the state. The Smilow Cancer Hospital at Yale is an exceptional cancer facility in the Northeast combining both inpatient and outpatient care at one hospital.

YCC implements the highest quality patient- care, through groundbreaking innovations by cultivating the leadership in the field of cancer research and medicine by prioritizing the basic science integrated clinical programs for faculties.

In addition, YCC It has twelve multidisciplinary cancer programs including relevant cancer types in this project. It comprises a big repertoire of 358 faculties including physician/basic scientists, 15 NAS members and 12 HHMI investigators with a contribution of 3653 cancer research publications between 2012-2017. YCC ranks among the most comprehensive, well-funded institutions by NIH, NCI and private funding. YCC is extremely supportive of the faculty members in providing the internal and external support to facilitate the development of their professional and scientific career.

(Name)'s has a laboratory and personal office, common equipment rooms, cell culture facilities, and space for a secretarial assistant. Beyond this, (Name) relishes direct access to all shared facilities of the Department and the Comprehensive Cancer Center, as well as the Keck Technology Laboratory. These include human tissue services, research histology, Laser capture microscopy capabilities, laser scanning confocal microscopy, DNA synthesis, Mass-spectrometry, cell-sorting, and other technical services.

As a member of our faculty, (Name) relishes grant-administrative support, office supplies and department wide journal subscriptions on a shared basis with the other faculty. (Name) has full access to the clinical research information systems and cancer center.

Finally, beyond the above noted tangible support provided by the Institution, (Name) works in an outstanding, intellectual, and supportive environment, which is complimentary to the aims of his/her grant. His/her laboratory is closely associated and in proximity to several other outstanding cancer and (Department name) investigators at YCC, including Drs (Name) all of them including the collaborators whose labs are close by and that is instrumental in real time collaboration and free flow of knowledge.

As (Name) research program advances to a translational stage, there is an exceptional close collaborator, that routinely conducts clinical Trials to test experimental therapies. In addition, YCC has also built a strong research community, infrastructure, and environment of cell therapy with world class scientists and clinicians, who are participating actively in basic, translational, and clinical research on (Name therapies). In fact, the Smilow Cancer Hospital at Yale-New Haven Hospital has led multiple clinical trials of (Describe trial). These can seamlessly integrate the translational work resulting into optimal therapeutic options in the clinical setting.

(Funding Agency's Name) has a long reputable tradition of supporting cancer research in search for a cure. Under the current competitive grant environment, the (Name of the award) would have a profound effect on (Name)'s career, enabling him/her to explore high-risk, high-reward ideas and pioneering research projects. In summary, I offer my highest and most enthusiastic support for (Name) and his/her project, and strongly recommend him/her for this award. (Name) is a brilliant innovator in cancer research and his/her contribution in basic/clinical science will immensely impact institutional progress and success in cancer therapy.

Should you have any questions, please do not hesitate to contact me. Thank you.

Sincerely,

Director, YCC